Home / Business and Economy / Lilly Sues Over Unapproved Obesity Drug Sales
Lilly Sues Over Unapproved Obesity Drug Sales
12 Aug
Summary
- Eli Lilly filed six lawsuits against companies selling unapproved retatrutide.
- The FDA has declared compounding and selling unapproved GLP-1 products illegal.
- US Customs intercepted over 31,000 illicit GLP-1 drug units in fiscal year 2025.
Eli Lilly has initiated a vigorous legal campaign against unauthorized sales of its experimental obesity drug, retatrutide, by filing six lawsuits in the United States. These legal actions target businesses including compounding pharmacies, medical spas, and online retailers accused of marketing retatrutide products before regulatory approval.
Retatrutide is currently undergoing Phase 3 clinical trials for obesity and type 2 diabetes, with no global regulatory body having yet approved it for human use. In June 2026, the U.S. Food and Drug Administration (FDA) issued a statement clarifying that the sale and compounding of retatrutide and other unapproved GLP-1 products are illegal.
Lilly's Chief Medical Officer, Dr. David Hyman, highlighted the severe risks associated with these unverified and unapproved black-market products. The escalating demand for weight-loss treatments has unfortunately fueled a growing illicit online market. Lilly has referred over 200 entities to various regulatory and law enforcement agencies for action.
In a significant enforcement effort, U.S. Customs and Border Protection reported intercepting over 31,000 units of illicit GLP-1 drugs during fiscal year 2025. July 2026 alone saw a more than twofold increase in seizures, with nearly 90,000 vials confiscated, underscoring the scale of the problem.
